Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials.
Streck JM, Lee JW, Walter AW, Rosen RL, Gareen IF, Kircher SM, Herman BA, Carlos RC, Kumar S, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany C, Shanafelt TD, Wagner LI, Land SR, Park ER, Ostroff JS. Streck JM, et al. Among authors: neal jw. Cancer Epidemiol Biomarkers Prev. 2023 Nov 1;32(11):1552-1557. doi: 10.1158/1055-9965.EPI-23-0420. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37410096 Free PMC article.
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trials.
Walter AW, Lee JW, Streck JM, Gareen IF, Herman BA, Kircher SM, Carlos RC, Kumar SK, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Wagner LI, Land SR, Ostroff JS, Park ER. Walter AW, et al. Among authors: neal jw. Cancer. 2024 Feb 1;130(3):439-452. doi: 10.1002/cncr.35039. Epub 2023 Oct 5. Cancer. 2024. PMID: 37795845
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN 1512 Investigators. Neal JW, et al. Lancet Oncol. 2016 Dec;17(12):1661-1671. doi: 10.1016/S1470-2045(16)30561-7. Epub 2016 Nov 4. Lancet Oncol. 2016. PMID: 27825638 Free PMC article. Clinical Trial.
Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
Choi E, Luo SJ, Ding VY, Wu JT, Kumar AV, Wampfler J, Tammemägi MC, Wilkens LR, Aredo JV, Backhus LM, Neal JW, Leung AN, Freedman ND, Hung RJ, Amos CI, Le Marchand L, Cheng I, Wakelee HA, Yang P, Han SS. Choi E, et al. Among authors: neal jw. Cancer. 2024 Mar 1;130(5):770-780. doi: 10.1002/cncr.35069. Epub 2023 Oct 25. Cancer. 2024. PMID: 37877788
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV. Pennell NA, et al. Among authors: neal jw. J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16. J Clin Oncol. 2019. PMID: 30444685 Free PMC article. Clinical Trial.
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li FY, Neal J, Lemmon MA, Walther Z, Politi K, Goldberg SB. Grant MJ, et al. Clin Cancer Res. 2023 Jun 1;29(11):2123-2130. doi: 10.1158/1078-0432.CCR-22-3497. Clin Cancer Res. 2023. PMID: 36913537 Free PMC article.
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. Goldberg SB, et al. Among authors: neal jw. J Thorac Oncol. 2012 Oct;7(10):1602-8. doi: 10.1097/JTO.0b013e318262de4a. J Thorac Oncol. 2012. PMID: 22878749 Free PMC article. Clinical Trial.
326 results